Catalyst Pharmaceuticals (NASDAQ: CPRX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Catalyst Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Catalyst Pharmaceuticals Company Info
A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.
News & Analysis
Both of these biopharmas have major catalysts that are in play or drawing near.
These two stocks are entirely different, but they both make shareholders richer.
Things aren't as bad as they might seem.
It's practically printing cash, and even more is on the way.
Their low price tags belie their massive long-term potential.
This supercharged growth stock posted a new all-time high this week.
Having a small drug development pipeline is a big risk, but it also leaves the door open potentially for big gains.
These quiet biotechs are tightly focused and practically alone in their markets.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
CPRX earnings call for the period ending September 30, 2021.
CPRX earnings call for the period ending June 30, 2021.
CPRX earnings call for the period ending March 31, 2021.
CPRX earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.